MX2020004934A - Composiciones y metodos para el tratamiento de los trastornos inmunitarios utilizando cepas de bacterias inmunomoduladoras de lactococcus. - Google Patents

Composiciones y metodos para el tratamiento de los trastornos inmunitarios utilizando cepas de bacterias inmunomoduladoras de lactococcus.

Info

Publication number
MX2020004934A
MX2020004934A MX2020004934A MX2020004934A MX2020004934A MX 2020004934 A MX2020004934 A MX 2020004934A MX 2020004934 A MX2020004934 A MX 2020004934A MX 2020004934 A MX2020004934 A MX 2020004934A MX 2020004934 A MX2020004934 A MX 2020004934A
Authority
MX
Mexico
Prior art keywords
immune
methods
compositions
modulating
treating
Prior art date
Application number
MX2020004934A
Other languages
English (en)
Inventor
Brian Goodman
Maria Sizova
Holly Ponichtera
Andrea Itano
Mark Bodmer
Taylor A Cormack
Carolina Baez-Giangreco
Duncan Mchale
Kritika Ramani
Original Assignee
Evelo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evelo Biosciences Inc filed Critical Evelo Biosciences Inc
Publication of MX2020004934A publication Critical patent/MX2020004934A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En el presente documento se proporcionan métodos y composiciones relacionadas con cepas inmunomoduladoras de Lactococcus útiles como agentes terapéuticos.
MX2020004934A 2017-11-15 2018-11-15 Composiciones y metodos para el tratamiento de los trastornos inmunitarios utilizando cepas de bacterias inmunomoduladoras de lactococcus. MX2020004934A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762586604P 2017-11-15 2017-11-15
US201862660693P 2018-04-20 2018-04-20
US201862661459P 2018-04-23 2018-04-23
US201862721941P 2018-08-23 2018-08-23
PCT/US2018/061297 WO2019099682A1 (en) 2017-11-15 2018-11-15 Compositions and methods for treating immune disorders using immune modulating lactococcus bacteria strains

Publications (1)

Publication Number Publication Date
MX2020004934A true MX2020004934A (es) 2020-12-03

Family

ID=66539145

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004934A MX2020004934A (es) 2017-11-15 2018-11-15 Composiciones y metodos para el tratamiento de los trastornos inmunitarios utilizando cepas de bacterias inmunomoduladoras de lactococcus.

Country Status (13)

Country Link
US (2) US11266700B2 (es)
EP (1) EP3710024A1 (es)
JP (1) JP2021502970A (es)
KR (1) KR20200090189A (es)
CN (1) CN111787932A (es)
AU (1) AU2018367596A1 (es)
BR (1) BR112020009133A2 (es)
CA (1) CA3082578A1 (es)
CO (1) CO2020007142A2 (es)
MX (1) MX2020004934A (es)
SA (1) SA520411910B1 (es)
TW (1) TW201922270A (es)
WO (1) WO2019099682A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020536969A (ja) 2017-10-12 2020-12-17 アンフィヴェナ セラピューティクス，インク． Ｃｄ３結合タンパク質の投薬レジメン
WO2019099682A1 (en) 2017-11-15 2019-05-23 Evelo Biosciences, Inc. Compositions and methods for treating immune disorders using immune modulating lactococcus bacteria strains
WO2020252144A1 (en) * 2019-06-11 2020-12-17 Evelo Biosciences, Inc. Secreted microbial extracellular vesicles
WO2021022070A2 (en) * 2019-07-31 2021-02-04 Sanford Burnham Prebys Medical Discovery Institute Prebiotic-induced anti-tumor immunity
EP4135670A1 (en) * 2020-04-17 2023-02-22 Evelo Biosciences, Inc. Solid dosage forms with improved disintegration profiles
KR102523743B1 (ko) * 2020-07-20 2023-04-19 건국대학교 산학협력단 락토코커스 락티스 kc24 균주를 포함하는 퇴행성 신경질환 예방 또는 치료용 조성물
KR102461600B1 (ko) 2020-07-21 2022-11-02 주식회사 피토맵 N-당질화 돌연변이 벼, 이의 제조방법 및 이를 이용한 단백질 생산용 벼의 제조방법
CN111803476A (zh) * 2020-08-14 2020-10-23 华中科技大学协和深圳医院 芬戈莫德用于抑制革兰阳性细菌活性的用途
CN112442472B (zh) * 2020-11-30 2023-05-26 四川大学华西医院 抗艰难梭菌的重组乳酸乳球菌、活载体疫苗及其制备方法
US20240009255A1 (en) * 2020-11-30 2024-01-11 Md Healthcare Inc. Composition for preventing, treating or ameliorating eosinophilic inflammatory diseases or th2 hypersensitivity immune diseases comprising lactococcus lactis-derived vesicles
EP4285997A1 (en) * 2021-01-26 2023-12-06 Megmilk Snow Brand Co. Ltd. Composition for improving joint function
KR102391017B1 (ko) * 2021-07-13 2022-04-29 한국식품연구원 락토코커스 락티스 WiKim0133을 포함하는 암의 예방, 개선 또는 치료용 조성물
KR102700114B1 (ko) * 2021-08-11 2024-08-29 박병희 신규한 락토코쿠스 락티스 서브스페이시스 크레모리스 및 이의 용도
KR102696109B1 (ko) * 2021-10-06 2024-08-16 국립부경대학교 산학협력단 락토코커스 락티스 생육 촉진용 조성물
CN114540235B (zh) * 2022-03-04 2023-10-31 中国海洋大学 一种诱导乳酸菌休眠态的方法及其应用
WO2023192361A1 (en) * 2022-03-31 2023-10-05 Incelldx, Inc. Methods of treating a subject for fibromyalgia and compositions for use in the same
CN118006515B (zh) * 2024-04-08 2024-06-18 中国农业大学 一株乳酸乳球菌及其在制备治疗牛乳腺炎的药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6368586B1 (en) 1996-01-26 2002-04-09 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
US7101565B2 (en) * 2002-02-05 2006-09-05 Corpak Medsystems, Inc. Probiotic/prebiotic composition and delivery method
EP1593309B1 (en) * 2004-05-07 2014-06-25 Friesland Brands B.V. Dairy product with at least one characteristic of a dairy product mixture
JP2007269737A (ja) * 2006-03-31 2007-10-18 Morinaga Milk Ind Co Ltd インターロイキン産生調節剤、該インターロイキン産生調節剤を含む医薬組成物及び飲食品、並びにその製造方法
FI20075539L (fi) * 2007-07-12 2009-01-13 Valio Oy Maitohappobakteerit, joilla on proinflammatorisia ominaisuuksia
EP2251020A1 (en) * 2009-05-11 2010-11-17 Nestec S.A. Short-time high temperature treatment generates microbial preparations with anti-inflammatory profiles
US9907755B2 (en) 2013-03-14 2018-03-06 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
US20150017208A1 (en) * 2013-07-12 2015-01-15 National Yang-Ming University Lactic acid bacterium having immunomodulatory and anti-allergic effects
JP6325828B2 (ja) * 2014-02-04 2018-05-16 小林　孝 微粒子化した乳酸菌（ラクトコッカス・ラクティス・サブスピーシーズ クレモリスＨ−６１株（ＮＩＴＥ ＢＰ−０１７８７））を有効成分として含有するＴＧＦ−β２抑制剤並びにこれを含有するＴＧＦ−β２低下用薬剤及びＴＧＦ−β２低下用食品
WO2016144139A2 (ko) * 2015-03-11 2016-09-15 주식회사 엠디헬스케어 유산균 유래 세포밖 소포체를 유효성분으로 포함하는 염증질환의 예방 또는 치료용 조성물
EP3081227A1 (en) * 2015-04-15 2016-10-19 Institut National De La Recherche Agronomique Lactococcus lactis producing tslp or il-25 and their uses as probiotics and therapeutics
US20200138878A1 (en) * 2017-07-06 2020-05-07 Probionase Therapies Inc. Probiotic-based treatment of resistant chronic rhinosinusitis
WO2019099682A1 (en) 2017-11-15 2019-05-23 Evelo Biosciences, Inc. Compositions and methods for treating immune disorders using immune modulating lactococcus bacteria strains

Also Published As

Publication number Publication date
AU2018367596A1 (en) 2020-05-21
BR112020009133A2 (pt) 2020-10-13
CA3082578A1 (en) 2019-05-23
JP2021502970A (ja) 2021-02-04
KR20200090189A (ko) 2020-07-28
CN111787932A (zh) 2020-10-16
EP3710024A1 (en) 2020-09-23
CO2020007142A2 (es) 2020-06-19
WO2019099682A1 (en) 2019-05-23
US20220211773A1 (en) 2022-07-07
SA520411910B1 (ar) 2023-12-11
US20190231829A1 (en) 2019-08-01
US11266700B2 (en) 2022-03-08
TW201922270A (zh) 2019-06-16
WO2019099682A9 (en) 2019-07-04

Similar Documents

Publication Publication Date Title
MX2020004934A (es) Composiciones y metodos para el tratamiento de los trastornos inmunitarios utilizando cepas de bacterias inmunomoduladoras de lactococcus.
AR113881A1 (es) Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia
SA520412543B1 (ar) تركيبات وطرائق لعلاج السرطان والاضطرابات المناعية باستخدام جراثيم الفيونيلّة
MX2020002659A (es) Vesiculas extracelulares bacterianas.
WO2018112365A3 (en) Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii
MX2021006581A (es) Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia.
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
PH12019500494A1 (en) Formulations of (r)-2-amino-3-phenylpropyl carbamate
GB2541571A (en) Pharmaceutical compositions
PH12020500371A1 (en) Spirocycle compounds and methods of making and using same
CA2900779C (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
MX2017001279A (es) Usos y composiciones de la flagelina.
MX2018012902A (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
PH12017500836A1 (en) Transdermal formulations
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
PH12020500372A1 (en) Spirocycle compounds and methods of making and using same
PH12017501028A1 (en) Treatment of retinal degeneration using progenitor cells
MX2017006019A (es) Apilimod para uso en el tratamiento de melanoma.
MX2018005825A (es) Celulas inmunes modificadas y usos de las mismas.
MY191337A (en) Compositions for the treatment of hypertension and/or fibrosis
MX2018007468A (es) Composiciones de colageno 7 y metodos para usar las mismas.
PH12016501658A1 (en) Sialylated glycoprotein compositions and uses thereof
MY182818A (en) Compositions for the treatment of fibrosis and fibrosis-related conditions
NZ725354A (en) Transdermal formulations of pergolide and uses thereof
MX2016010967A (es) Nuevas composiciones para tratar lesiones neuronales mecanicas.